Otsuka America Pharmaceutical, Inc. drugs
6 results
Abilify (aripiprazole)
(ARIPIPRAZOLE)Otsuka America Pharmaceutical, Inc.
Usage: ABILIFY (aripiprazole) Tablets are indicated for the treatment of schizophrenia, acute manic and mixed episodes in Bipolar I Disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and Tourette's disorder.
Abilify maintena (aripiprazole)
(aripiprazole)Otsuka America Pharmaceutical, Inc.
Usage: ABILIFY MAINTENA (aripiprazole) is indicated for the treatment of schizophrenia in adults and for the maintenance monotherapy treatment of bipolar I disorder in adults.
Abilify mycite (aripiprazole)
(ARIPIPRAZOLE)Otsuka America Pharmaceutical, Inc.
Usage: ABILIFY MYCITE is indicated for treating adults with schizophrenia, bipolar I disorder (both acute and maintenance treatment), and as adjunctive therapy for adults with Major Depressive Disorder. It consists of aripiprazole tablets embedded with a sensor to track drug ingestion. Compliance improvement and real-time tracking are not established.
Jynarque (tolvaptan)
(tolvaptan)Otsuka America Pharmaceutical, Inc.
Usage: JYNARQUE is indicated for adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) to help slow the decline of kidney function.
Rexulti (brexpiprazole)
(brexpiprazole)Otsuka America Pharmaceutical, Inc.
Usage: REXULTI is indicated for the adjunctive treatment of major depressive disorder in adults, treatment of schizophrenia in adults and adolescents (13 years and older), and treatment of agitation associated with Alzheimer's dementia, though it is not approved for as-needed use for agitation in dementia patients.
Samsca (tolvaptan)
(tolvaptan)Otsuka America Pharmaceutical, Inc.
Usage: SAMSCA® is indicated for treating clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L) in patients, including those with heart failure and SIADH. It is not meant for urgent serum sodium increases to prevent neurological symptoms, nor is its symptomatic benefit established.